Digirad's New OptiCount Product Delivers Higher Sensitivity.Business Editors/Health/Medical Writers SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2004 Digirad Corp., the leader in solid-state imaging, announced today the release of its new OptiCount(TM) collimator collimator (kol´imātur), n a diaphragm or system of diaphragms made of an absorbent material and designed to define the dimensions and direction of a beam of radiation. that increases the organ sensitivity of Digirad's nuclear cardiology nuclear cardiology Imaging The use of nuclear imaging techniques in the noninvasive study of cardiovascular disease–eg, myocardial perfusion imaging, planar imaging, SPECT–single-photon-emission computed tomography, infarction imaging. imaging systems by an average of 15% per detector head, while maintaining the same level of reconstructed image spatial resolution (Data West Research Agency definition: see GIS glossary.) A measure of the accuracy or detail of a graphic display, expressed as dots per inch, pixels per line, lines per millimeter, etc. It is a measure of how fine an image is, usually expressed in dots per inch (dpi). . Additionally, when used in conjunction with Digirad's new third generation Solidium(TM) detectors, OptiCount collimation collimation /col·li·ma·tion/ (kol?i-ma´shun) 1. in microscopy, the process of making light rays parallel; the adjustment or aligning of optical axes. 2. improves organ sensitivity by at least 30% over specifications listed for some conventional competitive Anger cameras. Increased organ sensitivity generally correlates to improved image quality. "OptiCount collimation is an important product line extension that improves organ sensitivity in nuclear cardiology applications," said David Sheehan, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Digirad Corp. "While OptiCount offers increased organ sensitivity, the combination of the OptiCount product with Solidium technology also offers our customers an outstanding combination of enhanced sensitivity and reliability. OptiCount collimation represents an impressive milestone in nuclear cardiology that represents the first of many planned products and upgrades designed to improve performance for Digirad's solid-state cameras." The OptiCount product is available as an optional accessory on new solid-state gamma cameras or as an upgrade to Digirad's existing installed base of cameras. About Digirad Digirad Corp., a privately held company privately held company A firm whose shares are held within a relatively small circle of owners and are not traded publicly. , develops, manufactures and markets solid-state, digital gamma cameras to hospitals, imaging centers and physician offices. Digirad offers a comprehensive line of solid-state nuclear gamma cameras that can be used for the detection of many medical conditions See carpal tunnel syndrome, computer vision syndrome, dry eyes and deep vein thrombosis. including cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease . These high performance cameras produce outstanding image quality, and due to their lightweight and compact design, fit easily into small office spaces. Digirad Imaging Solutions, a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Digirad Corp., provides mobile turnkey, in-office leasing services for physicians who want to perform nuclear cardiology procedures, but do not have the capital, personnel or patient volume to justify purchasing a system. Both Digirad Corp. and Digirad Imaging Solutions are headquartered in San Diego. For more information, visit www.digirad.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Digirad Corporation. This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether current trends in sales, growth, revenue, customer satisfaction, technology development, sensitivity, reliance and performance improvements and product development will continue in the future. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion